Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04595474 · ClinicalTrials.gov registry record

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

A clinical trial of Type 1 Diabetes and Cirrhosis, Liver, sponsored by Joslin Diabetes Center.

Active
Registry status
533
Enrollment target
1
Study location

NCT04595474: Active study of Type 1 Diabetes and Cirrhosis, Liver, sponsored by Joslin Diabetes Center.

NCT04595474 is a study of Type 1 Diabetes and Cirrhosis, Liver that is active but no longer recruiting, run by Joslin Diabetes Center. The registered enrollment target is 533 participants, below the 764-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04595474, a study of Type 1 Diabetes and Cirrhosis, Liver, is active but no longer recruiting, sponsored by Joslin Diabetes Center.

ACTIVE NOT RECRUITING
Registry status
533 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Primary Outcome

Controlled Attenuation Parameter (CAP) will be used to define the presence of NAFLD

Interventions

  • DEVICE Transient Elastography

Study Locations (1)

Massachusetts

  • Joslin Diabetes Center - Boston

Trial Details

FieldValue
Enrollment Target 533 participants
Start Date 2021-01-14
Est. Completion 2025-12-30
Joslin Diabetes Center

73 total trials

What the registry record for NCT04595474 still lists

NCT04595474 is an observational study that tracks outcomes without assigning an intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap, below the 764-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (30% lower).

The record links to 5 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Transient Elastography is the first listed.

NCT04595474 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04595474 about?

NCT04595474 is a clinical study titled "Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes". The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be priori...

What is the current status of trial NCT04595474?

This trial is currently active not recruiting. The enrollment target is 533 participants. The study started on 2021-01-14. Estimated completion is 2025-12-30.

What conditions does trial NCT04595474 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Cirrhosis, Liver, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver, Fibrosis, Liver.

What interventions are being tested in trial NCT04595474?

The interventions under investigation include: Transient Elastography (DEVICE).

Who is sponsoring clinical trial NCT04595474?

This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04595474 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04595474's enrollment target sits among peer trials

533 16th of 198 higher than 183 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • NCT05793151 · 532 participants · NA

    Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

  • NCT06378866 · 532 participants · Phase 2

    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04595474, the US trial registry maintained by the National Library of Medicine. NCT04595474 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.